他汀类药物使用、预防性保健与前列腺癌死亡率之间的关联
该研究利用美国退伍军人事务部数据库构建2000至2015年确诊前列腺癌的队列,评估诊断前他汀使用与前列腺癌特异性死亡率(PCSM)的关系。结果显示,诊断前他汀使用者胆固醇和PSA筛查率更高;未调整筛查时他汀使用与PCSM改善相关,但调整筛查率后关联消失。
要点
- 诊断前他汀使用者胆固醇(90% vs 69%)和PSA(76% vs 67%)筛查率显著高于非使用者。
- 未纳入筛查变量时,他汀使用与PCSM改善相关(SHR 0.90,95%CI 0.84-0.97;p=0.004)。
- 调整胆固醇和PSA筛查率后,他汀使用与PCSM无显著关联(SHR 0.98,95%CI 0.91-1.06;p=0.59)。
核心结论
- 诊断前他汀使用与前列腺癌死亡率之间的关联在考虑筛查利用后不再显著。
研究设计与样本
- 基于退伍军人事务部信息计算基础设施的回顾性队列研究,纳入2000至2015年确诊前列腺癌患者68,432例。
主要发现
- 诊断前他汀使用者40,772例(59.6%),非使用者27,660例(40.4%)。
- 他汀使用者胆固醇筛查率90% vs 非使用者69%(p<0.001),PSA筛查率76% vs 67%(p<0.001)。
- 未调整筛查时,他汀使用与PCSM改善相关(SHR 0.90,95%CI 0.84-0.97;p=0.004)及全因死亡率改善相关(HR 0.96,95%CI 0.93-0.99;p=0.02)。
- 调整胆固醇和PSA筛查率后,他汀使用与PCSM无显著关联(SHR 0.98,95%CI 0.91-1.06;p=0.59),与全因死亡率也无显著关联(HR 1.02,95%CI 0.98-1.05;p=0.25)。
临床怎么用
- 临床解读他汀与前列腺癌预后的观察性关联时,需考虑健康使用者效应及筛查行为的混杂影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Increasing evidence indicates an association between statins and reduced prostate cancer-specific mortality (PCSM). However, significant bias may exist in these studies. One particularly challenging bias to assess is the healthy user effect, which may be quantified by screening patterns. We aimed to evaluate the association between statin use, screening, and PCSM in a dataset with detailed longitudinal information. METHODS: We used the Veterans Affairs Informatics and Computing Infrastructure to assemble a cohort of patients diagnosed with prostate cancer (PC) between 2000 and 2015. We collected patient-level demographic, comorbidity, and tumor data. We also assessed markers of preventive care utilization including cholesterol and prostate specific antigen (PSA) screening rates. Patients were considered prediagnosis statin users if they had at least one prescription one or more years prior to PC diagnosis. We evaluated PCSM using hierarchical Fine-Gray regression models and all-cause mortality (ACM) using a cox regression model. RESULTS: The final cohort contained 68,432 men including 40,772 (59.6%) prediagnosis statin users and 27,660 (40.4%) nonusers. Prediagnosis statin users had higher screening rates than nonusers for cholesterol (90 vs. 69%, p < 0.001) and PSA (76 vs. 67%, p < 0.001). In the model which excluded screening, prediagnosis statin users had improved PCSM (SHR 0.90, 95% CI 0.84-0.97; p = 0.004) and ACM (HR 0.96, 95% CI 0.93-0.99; p = 0.02). However, after including cholesterol and PSA screening rates, prediagnosis statin users and nonusers showed no differences in PCSM (SHR 0.98, 95% CI 0.91-1.06; p = 0.59) or ACM (HR 1.02, 95% CI 0.98-1.05; p = 0.25). CONCLUSION: We found that statin users tend to have more screening than nonusers. When we considered screening utilization, we observed no relationship between statin use before a prostate cancer diagnosis and prostate cancer mortality.
引用
- Kumar A, Riviere P, Luterstein E, et al. Associations among statins, preventive care, and prostate cancer mortality. Prostate Cancer Prostatic Dis. 2020. PMID: 32029930. doi:10.1038/s41391-020-0207-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。